Keros Therapeutics (KROS) Non-Current Assets (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Non-Current Assets data on file, last reported at $22.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets fell 16.32% year-over-year to $22.6 million; the trailing twelve-month figure through Dec 2025 stood at $95.5 million (down 3.78% YoY), and the FY2025 full-year result was $22.6 million, down 16.32% from the prior year.
• Non-Current Assets for Q4 2025 stood at $22.6 million, down from $23.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $27.2 million in Q3 2024 and bottomed at $1.7 million in Q1 2021.
• The 5-year median for Non-Current Assets is $22.1 million (2023), against an average of $16.5 million.
• The widest annual swing landed in 2023, when Non-Current Assets soared 466.39%; it then decreased 16.32% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $3.8 million in 2021, then jumped by 451.4% to $21.0 million in 2022, then increased by 8.18% to $22.7 million in 2023, then gained by 18.74% to $27.0 million in 2024, then fell by 16.32% to $22.6 million in 2025.
• The last three Non-Current Assets figures came in at $22.6 million (Q4 2025), $23.5 million (Q3 2025), and $24.4 million (Q2 2025), per Business Quant data.

Peer Comparison